

# Cellular Biomedicine Group

CBMG and Novartis sign manufacturing partnership

Business development  
update

Pharma & biotech

5 October 2018

**Price** **US\$17.29**  
**Market cap** **US\$318m**

Net cash (\$m) at Q218 + Novartis investment	74.8
Shares in issue	18.4m
Free float	73%
Code	CBMG
Primary exchange	NASDAQ
Secondary exchange	N/A

## Share price performance



%	1m	3m	12m
Abs	(20.7)	(13.3)	64.7
Rel (local)	(20.8)	(19.0)	44.0
52-week high/low	US\$23.6	US\$9.2	

## Business description

Cellular Biomedicine Group (CBMG) is a biotechnology company developing cell-based therapeutics with operations primarily in China. It has completed Phase II clinical trials of ReJoin, an autologous progenitor cell therapy for osteoarthritis, and Phase I for a similar allogeneic product (AlloJoin). It is also the exclusive manufacturing partner for Novartis's CAR-T therapy Kymriah in China.

## Next events

Kymriah Chinese regulatory progress	Upcoming
Anti-BCMA initiated	Q418
Andi-CD22 initiated	Q418

## Analysts

Nathaniel Calloway	+1 646 653 7036
Maxim Jacobs	+1 646 653 7027

[healthcare@edisongroup.com](mailto:healthcare@edisongroup.com)

[Edison profile page](#)

**Cellular Biomedicine Group is  
a research client of Edison  
Investment Research Limited**

Cellular Biomedicine Group (CBMG) announced it has signed an exclusive partnership with Novartis to manufacture the CAR-T therapy Kymriah in China. Novartis retains all marketing responsibility and CBMG will be entitled to both a mark-up on manufacturing costs and an escalating single-digit royalty on sales. Additionally, Novartis will take an equity stake in CBMG of approximately 9%: \$40m at \$27.43/share. Our valuation is lifted to \$535m (from \$353.1m).

Year end	Revenue (\$m)	PBT* (\$m)	EPS* (\$)	DPS (\$)	P/E (x)	Yield (%)
12/16	0.6	(18.1)	(1.34)	0.0	N/A	N/A
12/17	0.3	(20.1)	(1.40)	0.0	N/A	N/A
12/18e	0.1	(27.1)	(1.43)	0.0	N/A	N/A
12/19e	5.3	(21.6)	(1.09)	0.0	N/A	N/A

Note: \*PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

## Manufacturing in China a necessity

The other major companies involved in CAR-T have already established relationships with companies in China to bring their products to that market: Gilead with Fosun and Celgene with WuXi AppTec. This is in part necessary because the manufacturing of cell-based products for the Chinese market must be in China due to legislation, as well as for practical logistics concerns. CBMG has one of the most advanced CAR-T manufacturing footprints in the country, so was a natural choice for Novartis, which had no prior commercial Chinese CAR-T arrangement.

## Reforms lead to a faster pathway to profitability

There have been numerous changes in China regarding both the treatment of cell based products as well as other pharmaceutical products. Cell therapies are now considered drugs, which allow them to be approved through similar pathways. These include expedited pathways for drugs that have been previously approved overseas, and priority review for novel products. With these factors combined, we believe that Kymriah could enter the Chinese market as early as 2019.

## Resources opened up for other internal programs

We assume that development will stop on CBMG's internal CD19 CAR-T programs as this would pose a conflict of interest for the new Novartis deal. However, this should free up significant capital for the company's other internal development programs. It has stated that it should have first-in-human studies for the company's anti-BCMA and anti-CD22 CAR-T product initiated by the end of 2018.

## Valuation: Increased to \$535m or \$29.07

We have increased our valuation to \$535m or \$29.07 per basic share from \$353.1m or \$20.76 per basic share. We have replaced the company internal C-CAR011 program with Kymriah in our models, which has a much higher probability of success (90%), and much sooner revenue ramp (manufacturing revenue in 2019). We also assume higher total sales (\$396m vs \$283m) considering the increased resources of Novartis.

## **CBMG to manufacture Kymriah for Novartis in China**

---

CBMG announced on 27 September 2018 that it entered into a licensing agreement with Novartis to manufacture the CAR-T therapy Kymriah (tisagenlecleucel) in China. Kymriah was the first CAR-T therapy to be approved and is currently marketed in the US, Canada and Europe for the treatment of diffuse large B-cell lymphoma (DLBCL) and pediatric acute lymphoblastic leukemia (ALL). CBMG will be entitled to an undisclosed mark-up on manufacturing costs as well as an escalating single-digit royalty on sales. CBMG will also provide a royalty free, worldwide license of some of its intellectual property to Novartis. Finally, Novartis is taking a 9% equity position in CBMG worth \$40m (at \$27.43 per share).

We view this as a very favourable relationship for all parties involved. It allows both CBMG and Novartis to leverage some of the regulatory reforms in China to quickly bring the product to market. Manufacturing based in China is obligatory for all cell-based products, because of legislation that limits the transport of human tissue out of China's borders. The other major western CAR-T companies have already established similar relationships with Chinese companies: Gilead has an agreement with Fosun and Celgene has an agreement with Wuxi AppTec (although neither currently market product). We should note that the structure of these agreements is fundamentally different from those between Novartis and CBMG. The Gilead-Fosun joint venture is largely a technology transfer, in which Fosun supplies all upfront costs as well as profit sharing and milestones to Gilead in exchange for its IP. The Celgene-Wuxi agreement is the formation of a new company (JW Therapeutics) jointly owned by both parties.

Additionally, there have been a series of regulatory changes in China that should enable treatments developed under such agreements to quickly enter the Chinese market. In December 2017, the National Medical Products Administration (NMPA, formerly the CFDA) announced that it would regulate cell therapies as drugs. Before this point, there was little clarity on how these products would be regulated and approved. Additionally, it opened up priority designations designed to enable quicker review and quicker market entry. In October 2017, the State Council announced a draft proposal that would allow foreign clinical data to be used for the approval of drugs in China. Previously, drugs approved overseas were required to perform at minimum Phase III studies in China. Under the new regime, applications are only required to include clinical data on 'the existence of ethnic differences'. Additionally, we should expect Kymriah to qualify as an innovative drug product and therefore be entitled to priority review at the NMPA. According to the government's audit of review times for 2017, the average review time for a priority review NDA application was 59 days. These pathways have not yet been tested for cell therapies, but the Chinese government has shown considerable initiative in promoting the development and approval of CAR-T and other cell therapies through these and other regulatory measures.


## **Development focus shifts to other internal products**

---

CBMG was previously developing its own CAR-T product C-CAR011 for the treatment of DLBCL and ALL, which were in Phase I clinical trial and expected to produce results in mid-2018. This product was based on similar technology to Kymriah, an anti-CD19 CAR-T receptor, and therefore presents a conflict of interest with the new agreement. The company has not explicitly disclosed the status of these programs, but we hypothesize that the intellectual property transfer included in the agreement is in regards to these products. We do not expect further clinical development of CD19-based CAR-T products, but the company did state that it will continue to develop its immunoncology assets (Exhibit 1). The company has communicated accelerated timelines with these programs: its anti-BCMA CAR-T program and anti-CD22 CAR-T programs are slated to initiate first-in-human

trials in Q418, with many following in 2019. We expect that this is made possible by the capital freed up by discontinuing C-CAR011, and we expect it to be further supported by the revenue from Novartis in the future. Additionally, the company intends to file INDs with the NMPA to initiate pivotal trials for both AlloJoin and ReJoin in Q418.

**Exhibit 1: CBMG pipeline**



Source: Cellular Biomedicine Group

## Valuation

We have increased our valuation to \$535m or \$29.07 per basic share from \$353.1m or \$20.76 per basic share. This increase is driven by a number of factors relating to the Novartis deal. We predict a 90% probability of approval in China for Kymriah, compared to the 20% probability for C-CAR011. We expect a low regulatory hurdle for the product, with few or no additional clinical data needed, although we may revise this in the future based on company feedback. We initial manufacturing revenue in 2019 to prepare for a launch in 2019 or 2020, although we admit that the pace of an NDA review for a cell product in China is untested. We have increased our peak sales estimates (\$396m total from \$283m) compared to C-CAR011 as well, due to Novartis's greater resources. Our pricing model remains unchanged, albeit at a lower launch price (\$76,000 vs \$84,000) as it will now occur before future price growth. Likewise, our market estimates remain unchanged, and we only consider patients covered by urban insurance schemes a viable market. CBMG is entitled to a mark-up over manufacturing costs, which we estimate at 50%, and we model a sales royalty of 4-8%, which corresponds to an average payment to the company of 17% of sales. Finally, we also include the \$40m in equity investment from Novartis, although this includes 1.5m additional shares. We may revise some aspects of this model in the future if more information regarding the agreement is released, or a more detailed commercial timeline is presented.

**Exhibit 2: Valuation of Cellular Biomedicine Group**

Development Program	Region	Prob. of success	Launch year	Peak sales (\$m)	Margin/license and royalties	rNPV (\$m)
Kymriah (DLBCL)	China	90%	2019	253	17%	146.3
Kymriah (ALL)	China	90%	2019	143	17%	82.8
ReJoin	China	40%	2021	144	31%	44.3
AlloJoin	China	40%	2022	431	58%	222.6
AlloJoin/ReJoin cannibalism	China					-35.3
<b>Total</b>						<b>460.7</b>
Net cash and equivalents (Q218 + Novartis purchase) (\$m)						74.8
Total firm value (\$m)						535.5
Total shares (m)						18.4
<b>Value per basic share (\$)</b>						<b>29.07</b>
Options (m)						1.9
Value per diluted share (\$)						27.49

Source: Cellular Biomedicine Group reports, Edison Investment Research

## Financials

The Novartis agreement has substantially affected the financial outlook for the company. Given the combination of the \$40m equity investment, much sooner revenue generation from the manufacturing agreement and reduced costs, we do not expect CBMG to require additional capital before profitability in 2021 (previously \$90m in capital needed to reach profitability in 2022). We no longer include development costs associated with C-CAR011 in our forecasts, although we have increased development of the company's other pipeline products, a trend that has already been reflected in Q218 financials: \$9.2m in R&D costs vs \$6.7m in Q217 due to 'pick-up in our development work and new talents recruited for anti-BCMA target for multiple myeloma, and other solid tumor indications.' Otherwise our forecasts, including those for the AlloJoin and ReJoin programs, remain unchanged.

**Exhibit 3: Financial summary**

	\$'000s	2016	2017	2018e	2019e
31-December		US GAAP	US GAAP	US GAAP	US GAAP
<b>INCOME STATEMENT</b>					
Revenue		627.9	336.8	128.3	5,256.6
Cost of Sales		(860.4)	(162.2)	(76.7)	0.0
Gross Profit		(232.5)	174.6	51.6	5,256.6
EBITDA		(15,716.2)	(19,245.4)	(22,703.0)	(17,545.8)
Normalised operating profit		(18,351.2)	(22,231.4)	(27,404.9)	(22,247.7)
Amortisation of acquired intangibles		(4,611.7)	0.0	0.0	0.0
Exceptionals		0.0	0.0	(29.4)	0.0
Share-based payments		(5,452.4)	(5,345.2)	(5,345.2)	(5,345.2)
Reported operating profit		(28,415.3)	(27,576.6)	(32,779.6)	(27,593.0)
Net Interest		78.9	133.6	215.7	643.7
Joint ventures & associates (post tax)		0.0	0.0	0.0	0.0
Exceptionals		132.1	1,955.1	93.9	0.0
Profit Before Tax (norm)		(18,140.2)	(20,142.6)	(27,095.3)	(21,604.0)
Profit Before Tax (reported)		(28,204.3)	(25,487.9)	(32,470.0)	(26,949.3)
Reported tax		(4.1)	(2.5)	0.0	0.0
Profit After Tax (norm)		(18,140.2)	(20,142.6)	(27,095.3)	(21,604.0)
Profit After Tax (reported)		(28,208.4)	(25,490.3)	(32,470.0)	(26,949.3)
Minority interests		0.0	0.0	0.0	0.0
Discontinued operations		(1,000.6)	727.2	0.0	0.0
Net income (normalised)		(18,140.2)	(20,142.6)	(27,094.3)	(21,602.0)
Net income (reported)		(29,209.0)	(24,763.1)	(32,470.0)	(26,949.3)
Basic average number of shares outstanding (m)		14	14	19	20
EPS - basic normalised (\$)		(1.34)	(1.40)	(1.43)	(1.09)
EPS - diluted normalised (\$)		(1.34)	(1.40)	(1.43)	(1.09)
EPS - basic reported (\$)		(2.16)	(1.73)	(1.71)	(1.35)
Dividend (\$)		0.00	0.00	0.00	0.00
<b>BALANCE SHEET</b>					
Fixed Assets		27,936.4	36,635.4	36,872.4	36,507.8
Intangible Assets		21,771.4	20,098.5	19,217.7	19,217.7
Tangible Assets		4,117.7	12,973.3	12,608.7	12,244.1
Investments & other		2,047.3	3,563.5	5,046.0	5,046.0
Current Assets		40,692.1	24,526.9	67,063.0	46,020.1
Stocks		0.0	0.0	0.0	0.0
Debtors		452.7	1,105.8	284.0	284.0
Cash & cash equivalents		39,252.4	21,568.4	64,369.9	43,327.0
Other		987.0	1,852.7	2,409.1	2,409.1
Current Liabilities		(2,364.0)	(3,676.1)	(4,836.2)	(5,032.7)
Creditors		(216.2)	(225.3)	(428.2)	(624.7)
Tax and social security		(28.9)	(28.9)	(28.9)	(28.9)
Short term borrowings		0.0	0.0	0.0	0.0
Other		(2,119.0)	(3,422.0)	(4,379.1)	(4,379.1)
Long Term Liabilities		(370.5)	(183.6)	(87.6)	(87.6)
Long term borrowings		0.0	0.0	0.0	0.0
Other long term liabilities		(370.5)	(183.6)	(87.6)	(87.6)
Net Assets		65,894.0	57,302.5	99,011.6	77,407.6
Minority interests		0.0	0.0	0.0	0.0
Shareholders' equity		65,894.0	57,302.5	99,011.6	77,407.6
<b>CASH FLOW</b>					
Op Cash Flow before WC and tax		(15,716.2)	(19,245.4)	(22,703.0)	(17,545.8)
Working capital		(255.4)	(1,434.6)	488.6	196.5
Exceptional & other		103.9	2,086.6	312.3	643.7
Tax		0.0	0.0	0.0	0.0
Net operating cash flow		(15,867.7)	(18,593.4)	(21,902.1)	(16,705.5)
Capex		(2,733.4)	(10,192.9)	(4,371.5)	(4,337.3)
Acquisitions/disposals		0.0	0.0	0.0	0.0
Net interest		0.0	0.0	0.0	0.0
Equity financing		43,285.6	10,826.5	69,136.2	0.0
Dividends		0.0	0.0	0.0	0.0
Other		0.0	0.0	0.0	0.0
Net Cash Flow		24,684.4	(17,959.8)	42,862.6	(21,042.9)
Opening net debt/(cash)		(14,884.6)	(39,252.4)	(21,568.4)	(64,369.9)
FX		(316.6)	275.8	(61.2)	0.0
Other non-cash movements		0.0	0.0	0.0	0.0
Closing net debt/(cash)		(39,252.4)	(21,568.4)	(64,369.9)	(43,327.0)

Source: Cellular Biomedicine Group reports, Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the [Financial Conduct Authority](#). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Pty Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. [www.edisongroup.com](http://www.edisongroup.com)

#### DISCLAIMER

Copyright 2018 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Cellular Biomedicine Group and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Investment Research Pty Ltd (Corporate Authorised Representative (1252501) of Myonlineadvisers Pty Ltd (AFSL: 427484)) and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") © FTSE 2018. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.